Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 13;118(15):4174-8.
doi: 10.1182/blood-2011-01-331181. Epub 2011 Aug 19.

Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC

Affiliations

Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC

Rahul Nahar et al. Blood. .

Abstract

Initial cell surface expression of the pre-B cell receptor induces proliferation. After 2 to 5 divisions, however, large pre-BII (Fraction C') cells exit cell cycle to become resting, small pre-BII cells (Fraction D). The mechanism by which pre-BII cells exit cell cycle, however, is currently unclear. The checkpoint at the Fraction C'-D transition is critical for immunoglobulin light chain gene recombination and to prevent malignant transformation into acute lymphoblastic leukemia. Here we demonstrate that inducible activation of pre-B cell receptor signaling induces cell-cycle exit through up-regulation of the transcriptional repressor BCL6. Inducible activation of BCL6 downstream of the pre-B cell receptor results in transcriptional repression of MYC and CCND2. Hence, pre-B cell receptor-mediated activation of BCL6 limits pre-B cell proliferation and induces cellular quiescence at the small pre-BII (Fraction D) stage.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pre-BCR signaling and Ikaros up-regulate BCL6 in normal and leukemic pre-B cells. Ighm−/− pro-B cells and Blnk−/− pre-BII cells were transformed with BCR-ABL1 and pre-BCR signaling was reconstituted by retroviral expression of BLNK-GFP, CD8/μ-chain or GFP and CD8 empty vectors. BCL6 mRNA levels were measured by quantitative RT-PCR in (A; n = 2) and protein levels were determined by Western blot in (B; n = 2) using β-actin as loading control. IL-7–dependent pre-B cells from Rag2−/− tTA/μ-chain-transgenic mice were cultured in the presence of tetracycline, removal of which induced activation of transgenic μ-chain expression under endogenous transcriptional control elements. Inducible differentiation was verified by flow cytometry (supplemental Figure 2) and BCL6 and MYC protein levels were measured by Western blot (C; n = 2). Normal IL-7–dependent pre-B cells were transduced with a constitutively active (CA) mutant of FoxO1 or an empty vector (transduction efficiency shown in supplemental Figure 1). After inducible activation with 4-hydroxy-tamoxifen (4-OHT), cells were subjected to Western blot analysis for BCL6 and β-actin as loading control (D; n = 2). Likewise, normal IL-7–dependent pre-B cells from Ptenfl/fl mice (supplemental Table 4) were transduced with 4-OHT–inducible Cre-ERT2 or an ERT2 empty vector control and subjected to antibiotic selection. Cre-mediated deletion of Pten and BCL6-up-regulation on IL-7 withdrawal was studied by Western blot using β-actin as loading control (E; n = 2). Pre-B ALL cells from Bcl6+/+ bone marrow were transduced with retroviral expression vectors for BCL6-GFP or a GFP empty vector control. The relative change of the percentage of GFP+ cells over time was measured by flow cytometry (F; n = 2). The cell-cycle profile of transduced cells was measured by BrdU incorporation and flow cytometry (G; n = 2) with statistical analysis (H). Pre-B ALL cells transduced with BCL6-GFP or GFP alone were sorted for GFP and transplanted into sublethally irradiated NOD/SCID mice via tail vein injection (3 mice per group). Spleens of recipient mice and their weight (right) are shown (I).
Figure 2
Figure 2
Pre-B cell receptor–mediated up-regulation of BCL6 inhibits proliferation by transcriptional repression of Myc. Pre-B ALL cells from Bcl6+/+ and Bcl6−/− bone marrow were transduced with retroviral expression vectors for CD8/μ-chain or CD8 alone. The relative change of the percentage of CD8+ cells over time was measured by flow cytometry (A; n = 3). To identify BCL6-target genes, ChIP-on-chip analysis was performed for 3 human BCR-ABL1 pre-B ALL cell lines (BV173, Tom1, Nalm1) and 2 human diffuse large B-cell lymphoma cell lines (OCI-Ly1 and OCI-Ly7) as positive controls. High expression levels of BCL6 were induced by treatment of BCR-ABL1 pre-B ALL cell lines with 10μM STI571 for 24 hours (STI571). Recruitment to CCND2 and MYC (see supplemental Figure 3) promoters are shown and to the HPRT promoter as a negative control. The ChIP-on-chip data for Myc in Nalm1 cells is also published in Duy et al. (B) BCR-ABL1 pre-B ALL cells were transduced with 4-hydroxy-tamoxifen (4-OHT)–inducible vectors for BCL6-ERT2 and ERT2 empty vector control. Myc mRNA (C; n = 2) and protein (D; n = 2) levels on 4-OHT induction were measured by quantitative RT-PCR and Western blot, respectively. Induction of BCL6 also resulted in up-regulation of Cdkn1b (p27) protein levels (D). Overexpression of Myc was sufficient to partially rescue BLNK/BCL6-mediated inhibition of proliferation (E): Blnk−/− BCR-ABL1 pre-B ALL cells were transduced with Myc-Puro or a Puro-empty vector control and subjected to antibiotic selection. Subsequently, pre-BCR signaling was reconstituted by retroviral expression of BLNK-GFP or a GFP empty vector control and proliferation of the Myc-Puro versus Puro-transduced cells was measured as relative change of the percentage of BLNK-GFP+ or GFP+ cells (E; n = 2).

References

    1. Decker DJ, Boyle NE, Koziol JA, Klinman NR. The expression of the Ig H chain repertoire in developing bone marrow B lineage cells. J Immunol. 1991;146(1):350–361. - PubMed
    1. Hess J, Werner A, Wirth T, Melchers F, Jäck HM, Winkler TH. Induction of pre-B cell proliferation after de novo synthesis of the pre-B cell receptor. Proc Natl Acad Sci U S A. 2001;98(4):1745–1750. - PMC - PubMed
    1. Kersseboom R, Middendorp S, Dingjan GM, et al. Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells. J Exp Med. 2003;198(1):91–98. - PMC - PubMed
    1. Jumaa H, Bossaller L, Portugal K, et al. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature. 2003;423(6938):452–456. - PubMed
    1. Flemming A, Brummer T, Reth M, Jumaa H. The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol. 2003;4(1):38–43. - PubMed

Publication types

MeSH terms